Product portfolio has included :Xeloda, Herceptin, Erivedge, Perjeta and Kadcyla; currently selling Metastatic and NeoAdjuvant infused therapy for Her2 Positive Breast Cancer Disease. Initially promoted Oral chemotherapy for Colorectal Cancer and Metastatic Breast Cancer. Oral Oncolytic for Metastatic Basal Cell Carcinoma and Locally Advanced Basal Cell Carcinoma. Achieved "Sales Excellence" 2012 in West Region Voted the "Essence" award from Chicago Division. Nominated for "Sales Consultant of the Year, 2012, 2013 for BioOncology West Region. Ranked 2nd in the BioOncology West Region (March 2013) and Promoted to Senior Clinical Oncology Specialist, September 2013.2015- Selected to be a part of the Product Team. Working as liaison between Chicago sales division and Home Office Brand Marketing team. Working on sub group for Kadcyla.2016- Selected for Home Office Rotation in South San Francisco

Successfully launched Zoledronic Acid, Reclast, IV treatment and ranked first in Indianapolis District. Launched Enablex for OAB to Urologists and OB/GYN with competing OAB products. Promoted and launched new indication with Exelon Patch for Alzheimer’s Disease. Launched Zelnorm for IBS to Gastroenterologists, Family Practice and Internal Medicine.• Recognized as National MVP Award winner for the Indianapolis District. • Placed 12th out of 260 of Midwest Operating Region, Enablex.• Attained 142% of goal with product launch for Enablex.• Served as key figure in District earning a #2 ranking in the Region as well as 16th nationally out of 390.• Won Midwest Region Summer Surge contest.• Became T2 New Product Growth Sales award winner, Enablex.• Worked with a wide variety of healthcare professionals, including Rheumatologists, Urologists, Endocrinologists, OB/GYN, Family Practice and Internal Medicine Healthcare Professionals.

Sales and marketing of Novartis cardiovascular brand products to Cardiologists and Family Practice Physicians. Developed key relationships with American Health Network and promoted from Innovex to Novartis within first year of contract after achieving sales above quotas.